Materias dentro de su búsqueda.
Mostrando 261 - 280 Resultados de 538 Para Buscar '"EUA"', tiempo de consulta: 0.25s Limitar resultados
  1. 261
    “…MATERIALS AND METHODS: Assessment included clinical and radiological assessment, examination under anesthesia (EUA), endoscopy of the lower GU tract, and evaluation of the surgical findings, operative procedures for the GU anomalies, and the results of management. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Congenital pouch colon in girls: Genitourinary abnormalities and their management
  2. 262
    “…The 2 groups were then compared with clinical evidence of engagement on examination under anesthesia (EUA) using video arthroscopy, number of dislocations, length of instability, and patient age. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical Application of the “Glenoid Track” Concept for Defining Humeral Head Engagement in Anterior Shoulder Instability: A Preliminary Report
  3. 263
    “…Therefore, four SARS-CoV-2 rRT-PCR kits have been approved by the emergency-use-authorization (EUA) without clinical validation in Korea until March 15, 2020. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of Four Commercial Kits for SARS-CoV-2 Real-Time Reverse-Transcription Polymerase Chain Reaction Approved by Emergency-Use-Authorization in Korea
  4. 264
    “…Nucleic acid amplification tests (NAATs), with emergency use authorization (EUA) by the FDA, have been subject to significant supply chain shortages. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    416. Comparative Analytical Assessment of PCR Mastermixes for Detection of SARS-CoV-2 using the CDC Diagnostic Test and the LightMix Modular Test on the cobas® z 480 Analyzer
  5. 265
    “…In March, testing was initially performed with the EUA Luminex NxTAG CoV Extended Panel until March 28, 2020 when testing was converted to the EUA Cepheid Xpert Xpress SARS-CoV-2 for quicker turnaround times. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    458. Molecular SARS-CoV-2 Testing During the COVID-19 Outbreak: Experiences of a Hospital in Southeast Michigan, USA
  6. 266
    “…In response, we developed SalivaDirect, which received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity
  7. 267
    “…BACKGROUND: Monoclonal antibody therapy (MAT) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with positive SARS-CoV-2 viral testing and at high risk for progression to severe COVID-19 with up to 10 days of symptoms. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    553. Outcomes in Patients Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection After Treatment with Monoclonal Antibody Therapy (MAT) in the Outpatient Setting
  8. 268
    “…BACKGROUND: The FDA has issued emergency use authorization (EUA) for neutralizing monoclonal antibodies (mAb) for the treatment of mild-moderate coronavirus disease 2019 (COVID-19) in patients who are at high risk of disease progression. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    519. Risk Factor Analysis for Hospital Admission Following Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Monoclonal Antibody Treatment
  9. 269
    “…BACKGROUND: Bamlanivimab (BAM), a neutralizing IgG1 monoclonal antibody (mAb), received emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for treatment of mild to moderate COVID-19 infection in patients 12 years of age and older weighing at least 40 kg at high risk for progressive and severe disease on Nov 10, 2020. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    549. Monoclonal Antibody Therapy for COVID-19 Infection in Michigan: The Flint Experience
  10. 270
    “…This may reflect the expanded time frame for EUA therapy as compared to clinical trials, differences in real world patients or viral variants. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    514. Anti-SARS-CoV-2 Monoclonal Antibodies for Early COVID-19: A Real World Experience
  11. 271
    “…As of 31 December 2021, the median number of vaccines provided with EUA was 6 for group 1, 11 for group 2, 8 for group 3 and 9 for group 4. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Inequities in the deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region, 2020–2021
  12. 272
    “…We developed a distinct SARS-CoV-2 diagnostic assay based on the original CDC Diagnostic Panel (EUA200001), yet, with minimum overlap for currently employed reagents to eliminate direct competition for limited resources. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Singleplex, multiplex and pooled sample real-time RT-PCR assays for detection of SARS-CoV-2 in an occupational medicine setting
  13. 273
    “…. • This is a summary of FDA emergency use authorization(EUA) recommended nucleic acid diagnostic modalities.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Recent Advances in Molecular diagnosis curbing the COVID-19
  14. 274
    “…In this article we will highlight what is behind adeno-associated vectors, such as those presented by the immunogens ChaAdOx1, Sputnik, Convidecia (CanSino, Tianjin, China), and Janssen (Johnson & Johnson, New Jersey, EUA), in addition to other promising platforms such as Vaccinia virus MVA, influenza virus, and measles virus, among others.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis
  15. 275
    “…RESULTS: Based on the docking scores predicted by ADV and AD, most vortioxetine derivatives showed better binding efficiency towards M(pro) of SARS-CoV-2 in comparison with remdesivir (an EUA approved drug against SARS-CoV-2 M(pro)) and vortioxetine. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor
  16. 276
    “…Few have been issued FDA EUA or recommendation by the Infectious Diseases Society of America (IDSA). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunomodulatory therapies for COVID-19
  17. 277
    “…Abbreviations: CoVIC: The Coronavirus Immunotherapeutic Consortium; EUA: Emergency Use Authorization…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pandemic’s silver lining
  18. 278
    “…Patients not meeting EUA criteria or receiving other outpatient antivirals were excluded (Figure 1). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    508. Nirmatrelvir/ritonavir use among patients with cancer and COVID-19 is associated with improved clinical outcomes: Single-institution case-control study
  19. 279
    “…The sotrovimab cohort included pts meeting sotrovimab’s Emergency Use Authorization (EUA) criteria and receiving sotrovimab ≤ 10 days from diagnosis (index date = day of infusion). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    510. Real-world Effectiveness of Sotrovimab for COVID-19: Evidence from United States (US) Administrative Claims Data
  20. 280
    “…See Table 1 for results and EUA. Results were recorded as positive, negative, or equivocal. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    417. Comparative Assessment of Multiple SARS-CoV-2 Antibody and Neutralization Assays from Blood Samples in COVID-19 Infected Patients
Herramientas de búsqueda: RSS